论文部分内容阅读
目的 :探讨miR-210高表达与乳腺癌患者预后的关系。方法 :检索Pub Med、EMBASE、Web of Science和CNKI等数据库中关于miR-210高表达与乳腺癌预后关系的文献资料,按纳入标准筛选出相关文献,提取总生存率(overall survival,OS)、无复发生存率(recurrence-free survival,RFS)和无病生存率(disease-free survival,DFS)的风险比(hazard ratio,HR)及其95%可信区间(CI),用Stata软件进行分析合并。结果:按标准共纳入文献6篇,病例数585例,meta分析显示:和低表达组相比,miR-210高表达组OS的合并HR值为2.29(95%CI:0.89~5.91,P=0.086);miR-210高表达组DFS/RFS的合并HR值为2.81(95%CI:1.35~5.87,P=0.006)。结论:以现有相关研究结果的meta分析显示,miR-210的高表达是乳腺癌临床预后的不良因素。
Objective: To investigate the relationship between miR-210 overexpression and prognosis in patients with breast cancer. Methods: The literature about the relationship between miR-210 overexpression and prognosis of breast cancer in Pub Med, EMBASE, Web of Science and CNKI databases was searched. According to the inclusion criteria, relevant literature was screened and the overall survival (OS) The hazard ratio (HR) and 95% confidence interval (CI) of recurrence-free survival (RFS) and disease-free survival (DFS) were analyzed using Stata software merge. Results: There were 6 articles and 585 cases according to the standard. The meta-analysis showed that the HR of miR-210 overexpression group was 2.29 (95% CI: 0.89-5.91, P = 0.086). The combined HR of DFS / RFS with miR-210 overexpression was 2.81 (95% CI: 1.35-5.87, P = 0.006). Conclusion: Based on the existing meta-analysis of related research results, miR-210 overexpression is a poor prognostic factor in breast cancer.